A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.
Also called NCT07881458
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,000 participants
- Sponsor
- Registry
-
NCT07881458 -
2026-527230-31-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Brazil, China, Germany, Japan, Puerto Rico, Romania, South Korea, Spain, Taiwan
- Registry status
- Recruiting
Technical summary
Registry record NCT07881458. Randomized; double masking; primary purpose treatment. Start 2026-10-16 (actual); primary completion 2029-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- Acronym
- AMPLIFY-2
- Condition
- Obesity
- Condition
- Overweight
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- eloralintide and tirzepatide
- Intervention (Drug)
- Tirzepatide
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07881458- Content hash
7b236ec4ac4bd3b9aa65bc1e84a8c09c33fdbf4d7d0c962520af7957756d4463